Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy T Batchelor

Showing results (121-130 of 268) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideStuart A Grossman, Kathryn A Carson, Tracy T Batchelor, et al.
Nature Reviews. Clinical Oncology|April 1, 2009
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancerElizabeth R Gerstner, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Research|December 1, 2011
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusionA Gregory Sorensen, Kyrre E Emblem, Pavlina Polaskova, et al.
Nature Reviews. Disease Primers|June 15, 2023
Primary central nervous system lymphomaAndrés J M Ferreri, Teresa Calimeri, Kate Cwynarski, et al.
Neuro-Oncology Practice|August 7, 2019
Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case seriesJustin T Jordan, Julie J Miller, Tucker Cushing, et al.
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|June 10, 2016
Impact of histopathological transformation and overall survival in patients with progressive anaplastic gliomaAllen L Ho, Matthew J Koch, Shota Tanaka, et al.
Acta Neuropathologica Communications|May 1, 2019
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastomaShota Tanaka, Tracy T Batchelor, A John Iafrate, et al.
Neuro-Oncology|September 25, 2016
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Elizabeth R Gerstner, Xiaobu Ye, et al.
Acta Neuropathologica|November 17, 2010
Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomasGayatry Mohapatra, David A Engler, Kristen D Starbuck, et al.
Pageof 27

Showing results (121-130 of 268) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideStuart A Grossman, Kathryn A Carson, Tracy T Batchelor, et al.
Nature Reviews. Clinical Oncology|April 1, 2009
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancerElizabeth R Gerstner, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Research|December 1, 2011
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusionA Gregory Sorensen, Kyrre E Emblem, Pavlina Polaskova, et al.
Nature Reviews. Disease Primers|June 15, 2023
Primary central nervous system lymphomaAndrés J M Ferreri, Teresa Calimeri, Kate Cwynarski, et al.
Neuro-Oncology Practice|August 7, 2019
Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case seriesJustin T Jordan, Julie J Miller, Tucker Cushing, et al.
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|June 10, 2016
Impact of histopathological transformation and overall survival in patients with progressive anaplastic gliomaAllen L Ho, Matthew J Koch, Shota Tanaka, et al.
Acta Neuropathologica Communications|May 1, 2019
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastomaShota Tanaka, Tracy T Batchelor, A John Iafrate, et al.
Neuro-Oncology|September 25, 2016
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Elizabeth R Gerstner, Xiaobu Ye, et al.
Acta Neuropathologica|November 17, 2010
Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomasGayatry Mohapatra, David A Engler, Kristen D Starbuck, et al.
Pageof 27